多西紫杉醇联合顺铂治疗晚期乳腺癌临床观察

目的:观察多西紫杉醇联合顺铂方案治疗化疗后复发转移晚期乳腺癌的临床疗效和不良反应.方法:晚期乳腺癌32例其中包括既往应用蒽环类药物治疗18例,非蒽环类药物化疗14例.用多西紫杉醇70mg/m2,第1天静滴,顺铂25mg/m2,第1-3天静滴,21天为1周期,2周期后评价疗效.结果:32例中CR 3例,PR 14例,总有效率为53.1%,中位疾病进展时间9个月,中位生存期17.8个月.主要不良反应为骨髓抑制、恶心呕吐和脱发,但均可耐受.结论:多西紫杉醇顺铂联合治疗化疗后复发转移的晚期乳腺癌疗效确切,副作用较轻可耐受.     

泰索帝联合希罗达治疗蒽环类化疗失败复发转移性乳腺癌的临床研究

目的研究泰索帝联合希罗达治疗蒽环类药物治疗失败复发转移性乳腺癌的疗效和安全性.方法 18例蒽环类药物治疗失败的复发转移性乳腺癌患者均接受泰索帝联合希罗达方案治疗,随机分为A组:泰索帝75mg/m2静滴,第1天;希罗达950mg/m2口服,每日2次,第1～14天,每3周为1周期;B组:泰索帝37.5mg/m2静滴第1、8天;希罗达950mg/m2口服,每日2次,第1～14天,每3周为1周期.每周期评价疗效同时记录不良事件.结果 18例患者均可评价疗效,完全缓解(CR)无,部分缓解(PR)13例,有效率(CR PR)72%(13/18).A组有效率88.9%(8/9),B组有效率55.6%(5/9).两组共56周期可评价毒性反应,无严重不良事件导致死亡的患者,中性粒细胞减少是主要不良反应,Ⅲ～Ⅳ度占58.9%,A组Ⅳ度中性粒细胞减少30.9%,B组3.7%(P=0.012).结论泰索帝联合希罗达是治疗蒽环类药物治疗失败复发转移性乳腺癌的有效方案,其不良反应能够耐受.     

紫杉醇联合顺铂治疗晚期乳腺癌临床观察

目的:观察紫杉醇联合顺铂(TP方案)治疗蒽环类耐药的复发转移性晚期乳腺癌的疗效与安全性.方法:从2005年6月-2008年6月以TP方案治疗蒽环类耐药的复发转移性晚期乳腺癌28例,紫杉醇135mg/m2静滴,第1天;顺铂75mg/m2静滴,第一天,21天为1周期,2个周期末评价近期疗效及安全性.结果:28例患者中CR 1例(3.5%),PR 13例(46.4%),SD 8例(28.5%),PD 6例(21.4%),有效率50%,不良反应主要是骨髓抑制,恶心、呕吐、脱发.结论:TP方案治疗蒽环类耐药的复发转移性晚期乳腺癌疗效可靠,不良反应可耐受,可作为蒽环类耐药的复发转移性晚期乳腺癌的化疗方案.     

晚期乳腺癌应用紫杉醇与顺铂治疗的疗效观察

目的：观察国产紫杉醇（PTX）联合顺铂（DDP）方案对蒽环类耐药的晚期乳腺癌患者的临床疗效及毒副作用。方法：采用PTX135mg/m^2,加入生理盐水静滴3h,第1天;DDP80mg/m^2,静滴,第2～3天,每3周重复1次,行2周期治疗后判定疗效。结果：32例中CR4例,PR12例,NC12例,PD4例,有效率为50.0%。主要不良反应是脱发、白细胞减少,其它毒副反应均较轻微可耐受,无化疗相关死亡。结论：国产紫杉醇联合顺铂治疗蒽环类耐药的晚期乳腺癌有较好疗效,不良反应轻,是冶疗蒽环类耐药的晚期乳腺癌较好的方案。     

紫杉醇联合顺铂治疗晚期乳腺癌临床观察

目的：观察紫杉醇联合顺铂（TP方案）治疗蒽环类耐药的复发转移性晚期乳腺癌的疗效与安全性。方法：从2005年6月-2008年6月以TP方案治疗蒽环类耐药的复发转移性晚期乳腺癌28例,紫杉醇135mg／m^2静滴,第1天;顺铂75mg／m^2静滴,第一天,21天为1周期,2个周期末评价近期疗效及安全性。结果：28例患者中CR1例（3．5％）,PR13例（46．4％）,SD8例（28．5％）,PD6例（21．4％）,有效率50％,不良反应主要是骨髓抑制,恶心、呕吐、脱发。结论：TP方案治疗蒽环类耐药的复发转移性晚期乳腺癌疗效可靠,不良反应可耐受,可作为蒽环类耐药的复发转移性晚期乳腺癌的化疗方案。     

泰索帝治疗晚期乳腺癌

目的:观察泰索帝联合顺铂治疗晚期乳腺癌临床疗效及毒副作用。方法:晚期乳腺癌53例,治疗组17例:泰索帝30 mg/m2～40 mg/m2,第1天,第8天,第15天,顺铂40 mg,第1天～第3天,28 d为1周期,连用2周期～4周期;对照组36例:CTX600 mg/m2,ADM40 mg/m2,PDD40 mg第1天～第3天,3周～4周为1周期,连用2周期～4周期。结果:治疗组17例,CR3例,PR10例,NC3例,PD1例,有效率76.5 %;对照组36例,CR2例,PR17例,NC12例,PD5例,有效率52.8 %(P<0.05)。泰索帝组化疗毒副作用,主要是骨髓抑制,白细胞减少,腹泻、变态反应、支气管哮喘、脱发、外周神经炎。结论:以泰索帝 顺铂治疗晚期乳腺癌的疗效肯定,并优于CTX ADM PDD方案,毒副作用小,耐受性好。     

泰索帝联合顺铂治疗晚期乳腺癌22例临床观察

目的：观察泰索帝联合顺铂治疗晚期乳腺癌的疗效及毒副作用。方法：22例晚期乳腺癌患者，均有客观临床观察指标，采用泰索帝联合顺铂化疗2个～3个周期，观察其疗效及毒副作用。结果：22例病例CR4例，PR13例，总有效率77．3％。主要毒副作用为骨髓抑制。结论：泰索帝联合顺铂为治疗晚期乳腺癌有效的二线化疗方案，值得临床推广。     

培美曲塞联合奈达铂治疗晚期乳腺癌的近期疗效

目的观察培美曲塞联合奈达铂治疗晚期乳腺癌的近期疗效及不良反应。方法 29例经蒽环类或紫杉类等药物化疗失败的晚期乳腺癌患者,给予培美曲塞联合奈达铂治疗,具体方案为:培美曲塞500 mg/m2静滴,第1天;奈达铂75 mg/m2静滴,第2天;3周1疗程,至少化疗2个疗程后评价疗效及不良反应。结果 29例患者均可评价疗效及不良反应。2例完全缓解(CR),10例部分缓解(PR),8例疾病稳定(SD),9例疾病进展(PD),总有效(CR+PR)12例(41.4%);疾病控制(CR+PR+SD)20例(69.0%)。主要不良反应为骨髓抑制、皮疹和胃肠道反应,经对症处理后均缓解。结论培美曲塞联合奈达铂治疗晚期乳腺癌疗效可靠,毒性反应轻,可耐受。     

长春瑞滨联合顺铂治疗蒽环类化疗后的晚期乳腺癌疗效分析

目的:观察长春瑞滨(NVB)和顺铂(DDP)联合方案治疗既往经蒽环类药物化疗失败、晚期复发转移的乳腺癌患者的疗效及不良反应.方法:NVB 25mg/m2加人生理盐水50 ml静脉推注,d1,8;DDP 30mg/m2加入生理盐水250ml静脉滴注,d1,3,21天为1周期,至少用2个周期.结果:36例患者中完全缓解(CR)8.3%,部分缓解(PR)38.9%,总有效率为47.2%,主要不良反应为骨髓抑制,以白细胞减少多见,其中Ⅲ-Ⅳ度骨髓抑制发生率为36.1%.结论:NVB与DDP联合化疗对蒽环类药物治疗失败的晚期乳腺癌患者有较好疗效,不良反应可以耐受,值得临床推广应用.     

国产长春瑞滨联合顺铂治疗晚期乳腺癌39例疗效分析

目的:评价国产长春瑞滨(盖诺,NVB)联合顺铂治疗晚期乳腺癌的疗效和毒副反应。方法:39例晚期乳腺癌患者采用长春瑞滨联合顺铂化疗,NVB 25mg/m2静脉滴注第1、8天,顺铂30mg/m2静脉滴注第1~3天,21天~28天为1周期,3周期以上评价疗效。结果:CR 4例,PR 16例,NC 13例,PD 6例,有效率(CR PR)为51.3%(20/39),主要毒副反应为骨髓抑制及消化道反应。结论:长春瑞滨联合顺铂治疗晚期乳腺癌疗效确切,可望成为晚期乳腺癌的二线解救方案。     

泰索帝联合顺铂治疗蒽环类耐药性晚期乳腺癌28例

目的 观察泰索帝联合顺铂治疗蒽环类耐药性晚期转移性乳腺癌28例的疗效与毒副反应.方法 泰索帝75 mg/m2,静滴,d1;顺铂75 mg/m2,静滴,d2-4,同时给与水化、利尿、止吐以及抗过敏预处理等治疗,21 d为1周期.中位化疗周期数为3个(2～5个)周期.结果 28例均可评价疗效.完全缓解(CR)2例(7.1%),部分缓解(PR)13例(46.4%),稳定(SD)6例(21.4%),进展(PD)7例(25%),总有效(CR PR)15例(53.6%),中位肿瘤进展时间(TTP)5.6个月,1年生存率63.7%.主要毒副反应为骨髓抑制、恶心、呕吐.结论 泰索帝和顺铂联合治疗蒽环类耐药的晚期转移性乳腺癌疗效较好,毒副反应轻,耐受性较好,是蒽环类耐药性乳腺癌的有效治疗方案.     

Induction Docetaxel and Cisplatin Followed by Weekly Docetaxel and Cisplatin with Concurrent Radiotherapy in Locally Advanced Stage III Non Small Cell Lung Cancer (LA-NSCLC)-A Phase II Study

Purpose: The objective of this phase II study was to document the activity and to evaluate the toxicity of docetaxel and cisplatin as induction chemotherapy followed by concurrent docetaxel and cisplatin with thoracic radiation in locally advanced stage III non small cell lung cancer. Patients and Methods: Twenty-seven patients with stage III locally advanced non-small cell lung cancer received induction chemotherapy with two cycles of docetaxel 75mg/m2 and cisplatin 75mg/m2 D1 every 3 weeks. Patients without disease progress after induction chemotherapy were assigned to concurrent chemoradiotherapy 20mg/m2 docetaxel&25mg/m2 cisplatin administrated on day 1 every week for 6 weeks along with concurrent radiotherapy at a dose of 60Gy in 30 fractions (2 Gy/fraction and 5 fractions per week). The primary endpoint was to determine the overall response rate (ORR), the secondary endpoint was to evaluate time to progression (TTP) and safety profile. Results: After induction chemotherapy, the overall response rate (ORR) was 44.4%, 23 patients without disease progress were assigned to concurrent treatment with an overall response rate of 65%. Median survival time was 17 months, time to progression was 11.5 months and the one-year survival was 58%. Neutropenia was the most common toxicity during induction therapy (26% expressed grade 3-4) whereas esophagitis was the most common toxicity during concurrent phase (17.3% expressed grade 3-4); toxicities were manageable. Conclusion: Induction chemotherapy by docetaxel and cisplatin followed by weekly docetaxel and cisplatin with concurrent thoracic radiation therapy is feasible and tolerable. These results warrant further large randomized studies to document and confirm the effectiveness of this regimen. Key Words: Lung cancer , Docetaxel , Cisplatin , Concurrent chemoradiotherapy.     

两组解救方案治疗蒽环类耐药的晚期乳腺癌疗效观察

目的:比较两组化疗方案作为晚期乳腺癌蒽环类耐药患者的解救治疗疗效及不良反应.方法:采用多西紫杉醇(DXL) 顺铂(DDP)、长春瑞滨(NVB) 顺铂方案治疗蒽环类耐药的晚期乳腺癌64例,比较患者的近期有效率、不良反应、疾病进展时间及1年生存率.DXL DDP方案:DXL 60mg/m2,持续1小时静脉滴注,d1;DDP 30mg/m2d2～4.NVB DDP方案:NVB 25mg/m2d1,8;DDP 30mg/m2,d2～4,上述两个方案每3周为一个周期.结果:DXL DDP方案的总有效率为52.9%(18/34),其中CR 5.9%(2/34),PR 47.1%(16/34);中位疾病进展时间(TTP)8个月;中位生存时间18个月,1年生存率62.9%.NVB DDP方案的总有效率为43.3%(13/30),其中CR 3.3%(1/30),PR 40.0%(12/30);中位TTP 7个月;中位生存时间15个月,1年生存率54.8%.两组方案的主要不良反应为骨髓抑制及胃肠道反应.结论:两组方案对于蒽环类耐药的晚期乳腺癌患者均有较好疗效,不良反应可耐受,其近期疗效无明显差异.     

紫杉醇联合顺铂治疗57例晚期乳腺癌的临床疗效分析

目的：观察紫杉醇联合顺铂（DDP）方案治疗晚期乳腺癌（ABC）及蒽环类耐药性乳腺癌的疗效与安全性.方法：采用紫杉醇联合DDP方案治疗ABC 57例（其中含蒽环类耐药性乳腺癌26例）.紫杉醇175 mg/m^2,静脉滴入,d1（或分为d1、d8）;DDP 70 mg/m^2,静脉滴入,d1（或分为d1～d3）,加水化、利尿和止吐治疗,21 d为1个周期.本组中位化疗周期数为3个.结果：完全缓解6例,部分缓解24例,稳定16例,疾病进展11例,总的有效率52.6%（30/57）,26例蒽环类耐药性乳腺癌患者的有效率为61.5%（16/26）.治疗时一般情况较好者疗效（53.5%）好于一般情况差者（23.3%）,P=0.045.中位肿瘤进展时间7个月,1年生存率为61.4%,中位生存期为19个月.主要毒性反应为骨髓抑制及胃肠道反应.结论：紫杉醇和DDP联合方案治疗ABC,特别是蒽环类耐药性乳腺癌疗效较好,使用方便,毒性反应较轻.该方案是包括蒽环类耐药性ABC的有效解救治疗方案.     

多西紫杉醇联合顺铂治疗蒽环类耐药的晚期乳腺癌

Objective： To observe the effect and toxicity of docetaxel with cisplatin in anthracyclines-resistant advanced breast cancer. Methods： Forty-five female patients received docetaxel 60 mg/m^2 on dl and cisplatin 30 mg/m^2 on d1-d3 of every 28 days. Every patient was treated with at least 2 cycles and a median of 3 cycles （2-6 cycles ）. Results： Five patients achieved complete response （11.1%） and 18 partial response （40.0%）, 10 stable disease （22.2%）. The overall response rate was 51.1%. The clinical disease control rate was 73.3%, median time to tumor progression （TTP） was 7.8 months （1.0-34.5 months）, median survival time was 17.6 months （range 1.9-48.0 months）, and one year survival rate was 65.2%. The main side effect was marrow suppression. The treatment was well tolerated with grades Ⅲ and Ⅳ leukopenia in nine （20%） and ten （22.2%） patients. Conclusion： Combinative chemotherapy of docetaxel and cisplatin has a good anti-tumor activity on refractory advanced breast cancer with manageable toxicity.     

A phase II randomized study of two taxanes and cisplatin for metastatic breast cancer after anthracycline: a final analysis

OBJECTIVE: The purpose of the study is to compare two taxanes/cisplatin combinations for metastatic breast cancer in terms of time to disease progression, response rates and toxicity. METHODS: Between April 2000 and December 2002, 101 patients with advanced breast carcinoma, previously treated with an anthracycline but not with a taxane, were enrolled. Fifty patients were treated with docetaxel 60 mg/m2 and cisplatin 50 mg/m2, and 51 patients were treated with paclitaxel 175 mg/m2 and cisplatin 50 mg/m2. Each cycle repeated every 3 weeks. RESULTS: The overall response rate was 62.5 and 42.6% in the docetaxel and palcitaxel groups respectively (P = 0.06). Median time to disease progression was 9.8 and 6.5 months in docetaxel and paclitaxel groups respectively (P = 0.15). The median overall survival time was 22.7 months in the docetaxel arm and 22.4 months in the paclitaxel arm. Grade 3/4 arthralgia/myalgia, sensory neuropathy and anemia occurred more frequently in the paclitaxel arm, while more mucositis, fatigue and neutropenia occurred in the docetaxel arm. CONCLUSION: Taxane/cisplatin combinations were active for advanced breast cancer, while there appeared to be evidence in favor of a docetaxel/cisplatin combination. The toxicity in favor of docetaxel/cisplatin warrants future first-line clinical trials.     

Docetaxel and cisplatin as second-line chemotherapy for advanced non-small cell lung cancer

AIMS AND BACKGROUND: Docetaxel and cisplatin are both active against non-small cell lung cancer (NSCLC). This pilot study evaluated the efficacy and toxicity of docetaxel and cisplatin as second-line chemotherapy for patients with advanced NSCLC. PATIENTS AND METHODS: Eleven patients with advanced NSCLC who had no response to platinum-based treatment or had recurrence after a partial response were enrolled (2 stage III B, 9 stage IV; 8 men, 3 women). Median age was 58 years (range, 40 to 74 years). Seven patients had an Eastern Cooperative Oncology Group performance status of 0, and four had a performance status of 1. Four weeks or more after the end of previous therapy, all 11 patients received docetaxel 60 mg/m2 and cisplatin 80 mg/m2 on day 1 every four weeks. RESULTS: Two patients (18.2%) achieved a partial response,five (45.4%) patients had stable disease, and four (36.4%) patients showed progressive disease after initiation of second-line therapy. Median survival was 277 days. Median time to disease progression was 101 days, and the one-year survival rate was 36.4%. Hematological toxicities were moderate. Grade 3 and 4 leukocytopenia and neutropenia were observed in five (45.4%) patients. Grade 3 anemia occurred in one (9 .1%) patient. No severe non-hematological toxicities were observed except grade 3 nausea in two (18.2%) patients. CONCLUSIONS: The regimen of docetaxel and cisplatin has reasonable efficacy with moderate toxicity as second-line chemotherapy for patients with previously treated, advanced NSCLC.     

多西他赛联合顺铂治疗蒽环类耐药的晚期三阴性乳腺癌的临床观察

目的观察多西他赛联合顺铂治疗蒽环类耐药的晚期三阴性乳腺癌的疗效及安全性。方法 18例蒽环类耐药的晚期三阴性乳腺癌患者给予多西他赛75 mg·m-2,静滴,d1;顺铂25 mg·m-2,静滴,d1～3,3周重复,治疗后评价客观疗效及毒副反应。结果 18例患者均可评价疗效,PR 7例(38.9%),SD 8例(44.4%),PD 3例(16.7%),总有效率为38.9%。中位疾病进展时间为6.5个月。毒副反应主要为骨髓抑制和胃肠道反应。结论多西他赛联合顺铂方案治疗蒽环类耐药的晚期三阴性乳腺癌疗效确切,安全性较好。     

国产长春瑞滨联合顺铂治疗转移性乳腺癌的临床观察

目的：观察国产长春瑞滨(盖诺)联合顺铂方案治疗转移性乳腺癌的临床疗效。方法：运用盖诺(25mg／m^2 IV dl，d8)加顺铂(DDP80mg／m^32 IV d1)治疗转移性乳腺癌26例。结果：取得CR3例(11．5％)，PR12例(46．1％)，总有效率RR(CR PR)达57．6％。主要毒副作用为骨髓抑制，胃肠道反应和静脉炎。白细胞减少的发生率100％，其中Ⅲ-Ⅳ度达57．7％。恶心、呕吐的发生率92．3％，Ⅲ-Ⅳ度达11．5％。静脉炎的发生率15．4％。结论：国产长春瑞滨联合顺铂对转移性乳腺癌疗效确切，且毒性可以耐受，可以作为对蒽环类药物治疗后复发，转移乳腺癌患者的二线治疗方案。     

Monotherapy with paclitaxel as third-line chemotherapy against anthracycline-pretreated and docetaxel-refractory metastatic breast cancer

We describe a patient with anthracycline-pretreated and docetaxel-refractory metastatic breast cancer who achieved a complete response after third-line chemotherapy with paclitaxel. A 59-year-old woman underwent modified radical mastectomy for advanced cancer in her left breast after local arterial neoadjuvant chemotherapy with anthracycline. Postoperatively anthracycline-containing adjuvant therapy was administered. Pulmonary metastases occurred 15 months after surgery, which did not respond to 4 cycles of second-line chemotherapy with docetaxel, given at 60 mg/m(2) every 3 weeks. Therefore 210 mg/m(2) of paclitaxel was given every 3 weeks as third-line monotherapy and induced a complete response with grade 3 neutropenia and hair loss as the major adverse effects. We suggest that paclitaxel is potentially effective as third-line monotherapy for anthracycline-resistant and docetaxel-refractory metastatic breast cancer.